The Cure IBM Blog
Abcuro Raises $66 Million for New Phase 3 Ulviprubart Study in IBM
Abcuro has raised $66 million to move ulviprubart (ABC008) into a new Phase 3 clinical trial in inclusion body myositis (IBM). The company plans to begin the study later this year and will focus on people with less severe IBM. Abcuro CEO Alex Martin told Endpoints...
Abcuro to Close Long-Term Extension Study of Ulviprubart in Inclusion Body Myositis
Cure IBM has been informed by Abcuro that the company has made the decision to close ABC008-IBM-202, the open-label long-term extension study of ulviprubart in people with inclusion body myositis. This means that patients in the extension study will no longer have...
Ulviprubart in Inclusion Body Myositis—New Results and the Question of Clinically Meaningful Slowing
Abcuro has now presented more detailed results from its Phase 2/3 clinical trial of ulviprubart (ABC008) in inclusion body myositis (IBM). The new data do not change the formal outcome of the trial: in the full study population, the trial did not meet its primary...
Pioglitazone in Inclusion Body Myositis: An Early but Encouraging Study
A newly published study on pioglitazone in inclusion body myositis gives reason for cautious optimism, although the study was small and preliminary. The main goal was not to learn whether pioglitazone is effective in treating IBM, but to see if it could shift...
Ulviprubart in Inclusion Body Myositis—Phase 2/3 Trial Results
Abcuro has announced new trial results for ulviprubart in inclusion body myositis (IBM). Here is a clear, patient-friendly summary of the findings, safety results, and what may come next.
Volunteers Needed for COVAD-3 Autoimmune Disease Survey
Who Can Participate in the Survey? The international COVAD study team, led by Dr. Latika Gupta, is studying the subjective well-being of people living with autoimmune diseases, including inclusion body myositis (IBM). This is an important topic, since disabling...